OrbiMed

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to delivering innovative treatment options to patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to advance transformative medicines that can significantly improve patient outcomes.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.

Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. the company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors in treating undruggable disease targets.

Terremoto Biosciences is a biotechnology company focused on drug delivery and discovery, specializing in small-molecule medicines. The company utilizes lysine-based covalency to develop optimized therapies with enhanced clinical profiles and superior therapeutic benefits. Terremoto's innovative platform aims to improve existing medicines and create new treatments for serious diseases, contributing to advancements in the healthcare sector.

Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.

Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers.

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to delivering innovative treatment options to patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to advance transformative medicines that can significantly improve patient outcomes.

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

PharmEasy is a leading pharmacy aggregator in India that operates an online drug delivery platform aimed at enhancing the supply chain of pharmaceuticals. By digitizing the process, it connects patients with local pharmacy stores and diagnostic centers, ensuring they can easily access a wide range of medicines and healthcare products. The platform is designed to make healthcare services more accessible and affordable, emphasizing the importance of good health for everyone. Through its services, PharmEasy strives to simplify the healthcare experience for patients, allowing them to fulfill their medical needs efficiently.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in utilizing a proprietary platform that leverages endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in mRNA transcripts. This innovative approach aims to restore the production of functional proteins, addressing various genetic mutations that contribute to diseases. ADARx is developing a pipeline of therapeutics designed to treat a range of conditions, including genetic, cardiometabolic, complement-mediated, and central nervous system diseases, offering potential solutions for previously incurable ailments.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.

XinThera is a drug discovery company dedicated to developing precision medicines aimed at treating cancer and immunologic diseases. By utilizing advanced computational chemistry technologies, XinThera designs small molecule therapies that target well-validated and previously challenging targets in oncology and immunology. The company's focus on these promising targets enhances the potential for effective drug therapies, ultimately benefiting patients who face difficult-to-treat conditions.

Zentera Therapeutics is a biopharmaceutical company.

Pulnovo Medical specializes in the development and production of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on radiofrequency ablation technology, offering advanced solutions such as pulse radiofrequency ablation catheters and instruments. These pioneering products are designed to enhance the resilience and quality of life for patients suffering from pulmonary hypertension and heart failure. Pulnovo Medical holds global invention patents for its high-frequency ablation equipment and intravascular catheters, reflecting its commitment to advancing treatment methodologies in this critical area of healthcare.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, established in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on treatments for conditions related to intense pruritus, particularly in patients undergoing targeted anti-cancer therapies. Its lead asset, orvepitant, is an oral NK-1 antagonist designed to alleviate this specific symptom. Additionally, NeRRe is advancing other candidates, including NT-814, a dual NK-1 and NK-3 antagonist, and NT-949, which is ready for Phase I trials. The company also has NT-432, a clinical candidate targeting NK-1 receptors. NeRRe Therapeutics aims to address unmet medical needs through its innovative therapeutic approaches.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Sparrow Pharmaceuticals, founded in 2013 and based in Portland, Oregon, focuses on developing targeted therapies for conditions related to corticosteroid excess. The company aims to provide innovative treatment options for disorders linked to elevated levels of cortisol, which can arise from tumors or prolonged use of corticosteroid medications like prednisone. By addressing serious issues associated with hypercortisolism, Sparrow Pharmaceuticals seeks to enhance the management of autoimmune and inflammatory conditions, ultimately improving patient care and outcomes in this challenging medical area.

Theseus Pharmaceuticals is a Technology based company.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Clover Biopharmaceuticals is a clinical-stage biotechnology company based in Chengdu, China, focused on discovering and developing innovative biologic therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2007, the company utilizes its proprietary Trimer-Tag technology platform to create novel biologics that target trimerization-dependent pathways. Clover also offers integrated biopharmaceutical drug manufacturing services and has in-house capabilities for cGMP biomanufacturing, which support the development of select biosimilars. Through its research and development efforts, Clover aims to bring transformative therapies to the market.

Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.

Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.

VIVUS, Inc. is a specialty pharmaceutical company based in Campbell, California, focused on the development and commercialization of therapeutic products for obesity, diabetes, sleep apnea, and sexual health. The company offers Qsymia, a treatment for obesity designed to assist adults with a body mass index of 30 or greater, or 27 or greater with weight-related health issues, in managing their weight alongside a reduced-calorie diet and increased physical activity. VIVUS also provides PANCREAZE, which addresses exocrine pancreatic insufficiency, and STENDRA/SPEDRA, an oral medication for erectile dysfunction. Additionally, the company is advancing its pipeline with ongoing clinical studies for Qsymia to treat conditions such as obstructive sleep apnea and diabetes, as well as VI-0106 for pulmonary arterial hypertension. VIVUS has established collaborative agreements with several pharmaceutical firms to enhance its research and development efforts. Founded in 1991, VIVUS continues to focus on innovative solutions that address significant health issues facing patients.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.

BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, BioShin operates as a wholly-owned subsidiary of Biohaven Pharmaceutical Holding Company. The company is engaged in advancing clinical trials for various therapeutic approaches, including calcitonin gene-related peptide (CGRP) receptor antagonism aimed at treating migraine and pain, glutamate modulation targeting Alzheimer’s disease and anxiety disorders, and myeloperoxidase (MPO) inhibition to address inflammation and neurodegeneration. With a commitment to the Asia-Pacific region, BioShin leverages expertise from both global industry and academic settings to develop its late-stage product candidates.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Prelude Therapeutics is a clinical-stage biopharmaceutical company based in Wilmington, Delaware, founded in 2016. The company focuses on discovering and developing small molecule therapies designed to target critical mechanisms driving cancer growth and resistance. Its pipeline includes several candidates currently in Phase 1 clinical trials, such as PRT543, aimed at treating solid tumors and myeloid malignancies, and PRT811, which targets solid tumors like glioblastoma multiforme. Other development programs include PRT1419, a selective inhibitor of an anti-apoptotic protein, PRT2527, an inhibitor of CDK9, PRT-SCA2 for genomically selected cancers, and PRT-K4 for solid tumors. Prelude Therapeutics aims to provide innovative treatment options for patients facing refractory cancers.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Perfuse Therapeutics is a biotechnology company dedicated to developing innovative therapies for eye diseases, with a primary focus on glaucoma. The company aims to improve retinal perfusion, which is critical in addressing various retinal conditions. By utilizing a novel mechanism to enhance blood flow to the retina, Perfuse Therapeutics seeks to provide treatment options that can slow the progression of glaucoma, as well as other retinal diseases such as non-proliferative diabetic retinopathy and retinal vein occlusion. Through its research and development efforts, the company is working to advance the standard of care for patients suffering from these conditions.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.

Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.

Prothelia Incorporated is a biopharmaceutical company based in Milford, Massachusetts, established in 2007. The company specializes in developing innovative therapeutic proteins aimed at treating rare muscle diseases. Its primary focus is on a novel protein therapy designed for congenital muscular dystrophy type 1A, a rare condition that impacts around 4,000 patients in the United States. Through its research and development efforts, Prothelia seeks to address significant unmet medical needs within this patient population.

MabPlex International Ltd provides contract development and manufacturing of biopharmaceuticals including, monoclonal antibodies (mAbs), recombinant proteins, Antibody Drug Conjugates (ADCs) and bispecifics. It offers customized mammalian cell medium, cell banking, monoclonal antibodiy active pharmaceutical ingredient (API) manufacturing, and biologics and ADC fill and finish manufacturing. The company was founded in 2013 and is based in Yantai, China with an additional office in Fremont, California.

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Zentera Therapeutics is a biopharmaceutical company.

Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.

AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapeutic in Phase 1 clinical trials, aimed at treating anemia related to elevated hepcidin levels and fibrodysplasia ossificans progressiva. The company's third candidate, KER-012, focuses on disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, as well as pulmonary arterial hypertension. Founded in 2015 and based in Lexington, Massachusetts, Keros Therapeutics is recognized for its expertise in the role of the Transforming Growth Factor-Beta family of proteins, which regulate red blood cell and platelet production, along with muscle and bone maintenance.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR to address neurodegenerative and neuroinflammatory diseases. The company has successfully developed a series of novel molecules through innovative computational methods, followed by validation in clinically relevant assays. These inhibitors aim to improve memory consolidation and enhance long-term memory in patients suffering from these conditions. ProteKt Therapeutics has raised $4 million in a pre-A funding round and is a graduate of the FutuRx accelerator, which supports emerging biotechnology ventures.

Akeso, Inc. is a clinical-stage biopharmaceutical company based in Zhongshan, China, focused on the discovery, development, and commercialization of innovative therapies targeting oncology, immunology, and other therapeutic areas. The company has a diverse pipeline that includes over 30 drug candidates, with 17 currently in clinical trials. Notable developments include AK104, a PD-1/CTLA-4 bi-specific antibody, and Penpulimab (AK105), a monoclonal antibody in Phase III trials for non-small cell lung cancer. Akeso also develops AK112, a PD-1/VEGF bi-specific antibody for solid tumors, alongside other candidates for severe psoriasis and autoimmune diseases. The company collaborates with various pharmaceutical partners to enhance its research and development capabilities and aims to meet global medical needs with its next-generation therapeutic antibodies.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

Prelude Therapeutics is a clinical-stage biopharmaceutical company based in Wilmington, Delaware, founded in 2016. The company focuses on discovering and developing small molecule therapies designed to target critical mechanisms driving cancer growth and resistance. Its pipeline includes several candidates currently in Phase 1 clinical trials, such as PRT543, aimed at treating solid tumors and myeloid malignancies, and PRT811, which targets solid tumors like glioblastoma multiforme. Other development programs include PRT1419, a selective inhibitor of an anti-apoptotic protein, PRT2527, an inhibitor of CDK9, PRT-SCA2 for genomically selected cancers, and PRT-K4 for solid tumors. Prelude Therapeutics aims to provide innovative treatment options for patients facing refractory cancers.

Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and related conditions. Founded in 2003 and headquartered in Buffalo, New York, Athenex operates across North America and Asia, aiming to become a global leader in cancer treatment. The company has three primary segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Its clinical pipeline includes notable Orascovery product candidates, such as Oral Paclitaxel for metastatic breast cancer and various other oral formulations targeting different cancer types. Additionally, Athenex is developing Src Kinase inhibitors for skin cancers and immunomodulatory therapies, including T Cell Receptor Engineered T Cells and arginine deprivation therapy. Through collaborations and strategic partnerships, Athenex is engaged in extensive research and development activities to advance its therapeutic offerings and improve patient outcomes.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.